GE HealthCare Technologies (GEHC) has drawn investor attention after receiving FDA 510(k) clearance for its MIM Contour ProtégéAI+ 2.0 software, a new AI tool designed to support radiation therapy planning in oncology.

Despite the FDA clearance and recent focus on AI enabled imaging and software, GE HealthCare Technologies’ share price is trading at $61.59, with the 30 day share price return down 4.11% and the 1 year total shareholder return down 13.44%. This suggests recent momentum has been weaker even as management highlights growth in Imaging, Advanced Visualization Solutions and Pharmaceutical Diagnostics and completes the Intelerad acquisition.

If GE HealthCare’s push into AI tools has caught your interest, it could be a good time to broaden your search and check out 40 healthcare AI stocks

With GE HealthCare Technologies generating revenue of $20.98b and net income of $1.91b, yet the stock is down 13.44% over 1 year, investors are asking whether this weakness represents an opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 23% Undervalued

Based on the most followed narrative, GE HealthCare Technologies is priced below an estimated fair value of $79.72 compared with the last close at $61.59, which puts a spotlight on the assumptions behind that gap.

The pipeline of new high-impact products, like Radiopharmaceuticals, Total Body PET, and Photon Counting CT, is anticipated to drive future revenue growth and potentially improve margins.

Read the complete narrative. Read the complete narrative.

Want to understand why this fair value sits well above today’s share price? The story leans heavily on steady growth in earnings, expanding margins and a future profit multiple that assumes investors stay comfortable with GE HealthCare’s long term role in imaging, diagnostics and AI driven tools.

Result: Fair Value of $79.72 (UNDERVALUED)

However, investors in GE HealthCare Technologies still need to weigh tariff exposure and China regulatory uncertainty, either of which could disrupt earnings expectations that underpin this undervalued narrative.

Next Steps

Given this mix of concern and optimism around GE HealthCare Technologies, now is a good time to look through the numbers yourself and pressure test the assumptions. To see both sides of the story in one place, review the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond GE HealthCare Technologies?

If GE HealthCare Technologies has sharpened your interest, do not stop here. Use the Simply Wall Street Screener to uncover more stocks that could fit your approach.

• Target steady compounding potential by focusing on companies with reliable cash flows and balance sheets using the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for potential mispriced opportunities by scanning companies that combine quality fundamentals with subdued valuations through the 45 high quality undervalued stocks.
• Put income first by searching for companies with higher yields and resilient payout profiles via the 8 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.